A venture capital firm based in the UK and founded in 2020 invests in women-led businesses in biosciences. The firm centers on a USD $100M fund raised as two rounds, the first having $30M to invest. The funds are focused health-tech ventures, with the main goal to hold investors and businesses accountable for diversity in management and teams. Check sizes can range between USD $350k-1.5M. The firm engages with companies in early stages and can also help identify ventures that they can back at a later stage. If the firm decides to not move forward with an investment, they are happy to support and utilize their global network to provide warm introductions to other investors and KOLs they have relationships with. The firm acts as a co-investor and will not lead. The firm is open to meeting companies based in the US, UK, Europe, Australia, and Asia.
The firm does not invest in therapeutics and direct consumer marketing. The firm is interested in heavy sciences that have a technical element, including medical devices, diagnostics, and digital health. They may look at platforms that help identify therapeutics but will not look at pure therapeutics. The firm is indication-agnostic. The firm would like to see companies with a protectable IP.
The firm does not require founders to be female, but require female management team members. The firm typically do not sit on board or observer seats but may if a company were to request.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment